Kewaunee Scientific Corp /De/
KEQU Nasdaq· Laboratory Apparatus & Furniture
Last close · Oct 23, 2026
$32.79
KIRA · Stoqly’s AI analyst, in plain words
- Kewaunee Scientific Corp /De/ had $282M of revenue in fiscal 2026, up 17.3% on the year before. Over five years, revenue changed +13.8% a year on average.
- Its operating margin was 5.9%, down 1.5 pts: of every 100 in sales, about 6 is left after running the business.
- Kewaunee Scientific Corp /De/ made $9.6M of net profit in fiscal 2026. From fiscal 2017 to 2026, diluted EPS grew 7.6% a year.
- Free cash flow was $14.7M in fiscal 2026, 5.2% of revenue.
- Kewaunee Scientific Corp /De/ returned $0.0M to shareholders in fiscal 2026, 0% of free cash flow. The diluted share count rose 0.1%.
- Kewaunee Scientific Corp /De/ owes $10.6M more than it holds in cash, about 0.5 years of operating profit.
Market cap
$95.8M
P/E
11.9x
Revenue
$282M
Net income
$9.6M
Free cash flow
$14.7M
Operating margin
5.9%
Kewaunee Scientific Corp /De/ in 30 seconds · fiscal 2026
Are sales growing?
+17.3%
Yes. Sales grew 17.3% last year.
Does it make a profit?
3.4%
A little. It keeps 3.4% of every sale as profit.
Does profit turn into cash?
5.2%
Partly. 5.2% of sales ends up as free cash.
Is debt under control?
0.5x
Yes. It could repay its debt with 0.5 years of operating profit.
How healthy are the accounts?
5 / 9
Mixed. It passes 5 of 9 health tests.
How is the share priced?
11.9x
One share costs 11.9 times its yearly profit per share.
What Kewaunee Scientific Corp /De/ does
No business description yet.
- Fiscal year ends
- April 30, 2026
- Latest annual report
- 10-K · Jun 26, 2026
- Legal name
- KEWAUNEE SCIENTIFIC CORP /DE/
- CIK
- 0000055529
Kewaunee Scientific Corp /De/ · KEQU
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $169M | $219M | $204M | $240M | $282M |
| Revenue growth | 14.5% | 30.0% | −7.2% | 18.0% | 17.3% |
| Gross margin | 14.3% | 16.2% | 25.5% | 28.6% | 28.5% |
| Operating margin | −1.5% | 2.4% | 9.0% | 7.4% | 5.9% |
| Net income | −$6.1M | $0.7M | $18.8M | $11.4M | $9.6M |
| Net margin | −3.6% | 0.3% | 9.2% | 4.7% | 3.4% |
| Diluted EPS | −$2.20 | $0.25 | $6.38 | $3.83 | $3.22 |
| Cash | |||||
| Cash from operations | −$7.9M | −$3.8M | $19.6M | $14.8M | $18.6M |
| Capital expenditure | $1.9M | $4.1M | $4.4M | $2.2M | $3.9M |
| Free cash flow | −$9.8M | −$7.9M | $15.2M | $12.6M | $14.7M |
| FCF margin | −5.8% | −3.6% | 7.5% | 5.2% | 5.2% |
| Share buybacks | — | $0.0M | $2.0M | $1.6M | $0.0M |
| Share count change | 0.9% | 4.2% | 1.2% | 1.4% | 0.1% |
| Debt and strength | |||||
| Cash and short-term investments | $4.4M | $8.1M | $23.3M | $14.9M | $10.0M |
| Debt incl. finance leases | $1.9M | $3.8M | $3.4M | $38.9M | $20.5M |
| Shareholders' equity | $35.7M | $37.4M | $54.8M | $64.5M | $74.7M |
| Net debt / EBITDA | −15.5x | −0.5x | −0.9x | 1.1x | 0.5x |
| Current ratio | 2.2x | 2.2x | 2.4x | 2.2x | 2.2x |
| Interest coverage | −4.1x | 3.1x | 10.2x | 5.5x | 4.3x |
| Returns and quality | |||||
| Return on capital | −6.3% | 10.6% | 52.8% | 15.8% | 15.0% |
| Return on equity | −15.9% | 2.0% | 40.7% | 19.1% | 13.8% |
| Return on tangible equity | −17.2% | 2.0% | 34.2% | 33.4% | 20.9% |
| Piotroski F-score | 2 | 5 | 7 | 4 | 5 |
| Altman Z'' | 3.8 | 4.2 | 5.5 | 4.3 | 4.8 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$0.3M
2 insiders
Of sales under plans
0%
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Kewaunee Scientific Corp /De/ · KEQU
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $32.79 a share, the company is worth $95.8M: 11.9 times its earnings of the last four quarters.
Source: SEC EDGAR XBRL filings (CIK 0000055529). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.